Provided are therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A 2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof； therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A 2A receptor antagonistic activity, which has an affinity for the adenosine A 2A receptor 10 times or higher than that for the adenosine A 1 receptor, or a pharmaceutically acceptable salt thereof； and the like.
